Analyzing tumor DNA to predict response to cancer treatment in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the dynamics of circulating tumor DNA (ctDNA) to predict and monitor the response to Tyrosine Kinase Inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). It aims to establish a relationship between ctDNA levels and clinical responses to TKI treatment, comparing ctDNA dynamics with traditional imaging methods. Patients will provide blood samples for ctDNA analysis at multiple time points, and their clinical outcomes will be monitored over a two-year period. The study will also assess the correlation between ctDNA changes and progression-free survival and overall survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed.
* FFPE/FNA sample is available.
* Compliant with treatment protocol.
* Patients consented to participate in the study.

Exclusion Criteria:

* Patients already started TKI before enrollment.
* Patients already started chemotherapy before enrollment.
* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
* Patients did not agree to participate in the studies.

Where it's running

• Medical Genetics Institute
  Ho Chi Minh City, Vietnam Recruiting

Study contacts

• Principal investigator: Sinh D Nguyen, PhD — Mgi
• Study coordinator: Lan NL Tu, PhD
• Email: lantu@genesolutions.vn
• Phone: +84888843489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant SBRT then sintilimab with chemotherapy for N3-positive locally advanced NSCLC

  This approach tests whether focused radiation to the primary lung tumor followed by two cycles of sintilimab plus platinum-based chemotherapy before surgery can shrink N3-positive locally advanced non-small cell lung cancer and enable curative surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07309952

• Using enhanced immune cells to treat specific types of lung cancer

  This study is testing a new treatment using special immune cells and a drug to see if it can help people with advanced lung cancer that has certain genetic changes and hasn’t improved with previous treatments.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05681780

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.